Osteoarthritis and metabolic syndrome: a look at the phenotypical approach

Margarita A. Gromova , Oxana A. Kislyak , Antonina V. Starodubova , Yulia V. Liskova , Petr A. Kelekhsaev

For citation:

Abstract

Osteoarthritis associated with metabolic syndrome (MetOA) is a clinical phenotype defined by the role of obesity and metabolic syndrome as risk factors, as well as mild chronic inflammation. Obesity is an established risk factor for developing osteoarthritis (OA) not only in the knee but also in the hands. Metabolic syndrome is also a risk factor for the development of OA, and the cumulative effect of the various components of the syndrome is combined with the independent action of each individual component (diabetes mellitus, dyslipidemia and/or arterial hypertension). The higher incidence of OA in obese patients is associated with several factors. One of them is a large fat mass, which increases the stress on the joints. Another is the production of pro-inflammatory mediators by adipose tissue, which negatively affect the tissues of the joints. Finally, patients with OA, with or without metabolic syndrome, are at increased risk of cardiovascular mortality, not only due to a sedentary lifestyle, but also due to common risk factors. Among them is the mild inflammation seen in patients with metabolic disorders. Thus, primary prevention and appropriate treatment of obesity and metabolic syndrome can delay the development and slow the progression of OA.
Key words: osteoarthritis, metabolic syndrome, metabolic phenotype, risk factors, hypoglycemic drugs, statins, antihypertensive drugs, SYSADOA, diacerein.

References

1. Васильева Л.В., Лахин Д.И. Влияние метаболического синдрома на клиническую картину остеоартроза. Медицинский вестник Северного Кавказа 2017; 1: 8-11. [Vasil'eva L.V., Lahin D.I. Vlijanie metabolicheskogo sindroma na klinicheskuju kartinu osteoartroza. Medicinskij vestnik Severnogo Kavkaza 2017; 1: 8–11 (in Russian)].
2. Матвиенко Е.В., Хмелевская И.Г. Остеоартроз у подростков на фоне гипермобильного синдрома. Университетская наука: взгляд в будущее. Материалы международной научно-практической конференции, посвященной 81-летию Курского государственного медицинского университета и 50-летию фармацевтического факультета. Курск, 04–06 февраля 2016 года. Курск: Курский государственный медицинский университет, 2016. С. 111–6. [Matvienko E.V., Hmelevskaja I.G. Osteoartroz u podrostkov na fone gipermobil'nogo sindroma. Universitetskaja nauka: vzgljad v budushhee. Materialy mezhdunarodnoj nauchno-prakticheskoj konferencii, posvjashhennoj 81-letiju Kurskogo gosudarstvennogo medicinskogo universiteta i 50-letiju farmacevticheskogo fakul'teta. Kursk, 04–06 fevralja 2016 goda. Kursk: Kurskij gosudarstvennyj medicinskij universitet, 2016. S. 111–6 (in Russian)].
3. Закирова Д.Р., Бурганов Э.Р., Гайнутдинов А.Р., Хузина Г.Р. Фенотипическая классификация остеоартрита и возможности патогенетической терапии. Современная медицина 2018; 1(9): 188–91 [Zakirova D.R., Burganov Je.R., Gajnutdinov A.R., Huzina G.R. Fenotipicheskaja klassifikacija osteoartrita i vozmozhnosti patogeneticheskoj terapii. Sovremennaja medicina 2018; 1(9): 188–91 (in Russian)].
4. Лила А.М., Алексеева Л.И., Телышев К.А. Современные подходы к фенотипированию остеоартрита. Современная ревматология 2019; 13(2): 4–8. [Lila A.M., Alekseeva L.I., Telyshev K.A. Sovremennye podhody k fenotipirovaniju osteoartrita. Sovremennaja revmatologija 2019; 13(2): 4–8 (in Russian)].
5. Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г. и др. Новые возможности терапии у больных остеоартритом коленных суставов и метаболическим синдромом. Медицинский совет 2018; 1; 86–96. [Alekseeva L.I., Taskina E.A., Kashevarova N.G. et al. Novye vozmozhnosti terapii u bol'nyh osteoartritom kolennyh sustavov i metabolicheskim sindromom. Meditsinskii sovet 2018; 1; 86–96 (in Russian)].
6. Felson DT, Anderson JJ, Naimark A et al. Obesity and kneeosteoarthritis. The Framingham Study. Ann Intern Med 1988; 109: 18–24.
7. Jiang L, Xie X, Wang Y et al. Body mass index and hand osteoarthritis susceptibility: an updated meta-analysis. Int J Rheum Dis 2016; 19(12): 1244–54. DOI: 10.1111/1756-185X.12895
8. Visser AW, de Mutsert R, le Cessie S et al. The relative contribution of mechanical stress and systemicprocesses in different types of osteoarthritis: the NEO study. Ann Rheum Dis 2015; 74: 1842–7.
9. Gandhi R, Woo KM, Zywiel MG, Rampersaud YR. Metabolic syndrome increasesthe prevalence of spine osteoarthritis. Orthop Surg 2014; 6: 23–7.
10. Yoshimura N, Muraki S, Oka H et al. Accumulation of metabolic risk factors such as overweight, hypertension, dys-lipidaemia, and impaired glucose tolerance raises the risk of occurrence andprogression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthr Cartil 2012; 20: 1217–26.
11. Tomi AL, Sellam J, Lacombe K et al. Increased prevalence and severity of radiographic hand osteoarthritis in patients withHIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. Ann Rheum Dis 2016; 75: 2101–7.
12. Niu J, Clancy M, Aliabadi P et al. Metabolic syndrome, its compo-nents, and knee osteoarthritis: The Framingham Osteoarthritis Study. Arthritis Rheumatol 2017; 69: 1194–203.
13. Yasuda E, Nakamura R, Matsugi R et al. Association between the severity of symptomatic knee osteoarthritis and cumulativemetabolic factors. Aging Clin Exp Res 2018; 30: 481–8.
14. Shin D. Association between metabolic syndrome, radiographic kneeosteoarthritis, and intensity of knee pain: results of a national survey. J Clin Endocrinol Metab 2014; 99: 3177–83.
15. Schett G, Kleyer A, Perricone C et al.Diabetes is an independent predictor for severe osteoarthritis: results from alongitudinal cohort study. Diabetes Care 2013; 36: 403–9.
16. Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitusand osteoarthritis: systematic literature review and meta-analysis. RMD Open 2015; 1: e000077.
17. Williams MF, London DA, Husni EM et al. Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis. J Diabetes Complicat 2016; 30: 944–50.
18. Baudart P, Louati K, Marcelli C et al. Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open 2017; 3: e000442.
19. Zhang Y-M, Wang J, Liu X-G. Association between hypertension and risk of knee osteoarthritis: A meta-analysis of observational studies. Medicine (Baltimore) 2017; 96: e7584.
20. Veronese N, Stubbs B, Solmi M et al. Kneeosteoarthritis and risk of hypertension: a longitudinal cohort study. Rejuvenation Res 2018; 21: 15–21.
21. Atayde SA, Yoshinari NH, Nascimento DP et al. Experimental diabetes modulates collagen remodelling of joints in rats. Histol Histopathol 2012; 27: 1471–9.
22. Oren TW, Botolin S, Williams A et al. Arthroplasty in veterans:analysis of cartilage, bone, serum, and synovial fluid reveals differences andsimilarities in osteoarthritis with and without comorbid diabetes. J Rehabil Res Dev 2011; 48: 1195–210.
23. Laiguillon M-C, Courties A, Houard X et al. Characterization of diabetic osteoarthritic cartilage and role of highglucose environment on chondrocyte activation: toward pathophysiologi-cal delineation of diabetes mellitus-related osteoarthritis. Osteoarthr Cartil 2015; 23: 1513–22.
24. Vaamonde-Garcia C, Courties A, Pigenet A et al. The nuclear factor-erythroid 2-related factor/heme oxygenase-1 axis iscritical for the inflammatory features of type 2 diabetes-associated osteoarthri-tis. J Biol Chem 2017; 292: 14505–15.
25. Hamada D, Maynard R, Schott E et al. Suppres-sive effects of insulin on tumor necrosis factor-dependent early osteoarthriticchanges associated with obesity and type 2 diabetes mellitus. Arthritis Rheumatol 2016; 68: 1392–402.
26. de Munter W, van den Bosch MH, Slöetjes AW et al. High LDL levels lead to increased synovial inflammation and acceleratedectopic bone formation during experimental osteoarthritis. Osteoarthr Cartil 2016; 24: 844–55.
27. Gierman LM, Kühnast S, Koudijs A et al. Osteoarthritis development is induced by increased dietary choles-terol and can be inhibited by atorvastatin in APOE*3Leiden. CETP mice-atranslational model for atherosclerosis. Ann Rheum Dis 2014; 73: 921–7.
28. Chan PB, Wen C. Spontaneous hypertensive rat exhibits bone and meniscusphenotypes of osteoarthritis: is it an appropriate control for MetS-associated OA? Ann Rheum Dis 2018; 77: e25.
29. Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Zmijewski M, ed. Osteoarthr Cartil 2019; 27(11): 1578–89. DOI: 10.1016/j.joca.2019.06.011
30. Griffin TM, Huebner JL, Kraus VB et al. Induction of osteoarthritis andmetabolic inflammation by a very high-fat diet in mice: effects of short-termexercise. Arthritis Rheum 2012; 64: 443–53.
31. Bruunsgaard H. Physical activity and modulation of systemic low-level inflam-mation. J Leukoc Biol 2005; 78: 819–35.
32. Gomes WF, Lacerda AC, Mendonca VA et al. Effect of exercise on the plasma BDNF levels in elderly women with kneeosteoarthritis. Rheumatol Int 2014; 34: 841–6.
33. Алексеева Л.И. Новые представления о патогенезе остеоартрита, роль метаболических нарушений. Ожирение и метаболизм. 2019; 16(2): 75–82. [Alekseeva LI. New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders. Obesity and metabolism 2019; 16(2): 75–82 (in Russian)]. DOI: 10.14341/omet10274
34. Лила А.М., Мартынова Л.В., Лила В.А. Диацереин в терапии остеоартрита коленных суставов: результаты сравнительного исследования. РМЖ 2016; 2: 70–7. [Lila A.M., Martynova L.V., Lila V.A. Diatserein v terapii osteoartrita kolennykh sustavov: rezul'taty sravnitel'nogo issledovaniya. RMZh 2016; 2: 70–7. (in Russian)].
35. Лучихина Л.В., Каратеев Д.Е. Диацереин при остеоартрозе: открытое сравнительное исследование. Современная ревматология 2016; 10(1): 21–5. [Luchikhina L.V., Karateev D.E. Diatserein pri osteoartroze: otkrytoe sravnitel'noe issledovanie. Sovremennaya revmatologiya 2016; 10(1): 21–5. (in Russian)].
36. Shizhe Guo, Xianshan Guo, Hongya Zhang, Xuan’e Zhang, and Zhen Li. The Effect of Diacerein on Type 2 Diabetic Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. Journal of Diabetes Research. Volume 2020, Article ID 2593792, 9 pages
37. Guo S, Guo X, Zhang H et al. The Effect of Diacerein on Type 2 Diabetic Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. Zmijewski M, ed. J Diabetes Res 2020; 2020 (11): 1–9. DOI: 10.1155/2020/ 2593792
38. Nowrouzi-Sohrabi P, Tabrizi R, Jalali M et al. Effects of Diacerein Intake on Cardiometabolic Profiles in Type 2 Diabetics: A Systematic Review and Meta-Analysis of Clinical Trials. Curr Med Chem 2021; 28 (4): 840–52. DOI: 10.2174/0929867327666200728134755
39. Almezgagi M, Zhang Y, Hezam K et al. Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother 2020; 131: 110594.
40. Pelletier J-P, Raynauld J-P, Dorais M et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology 2020; 59(12): 3858–68. DOI: 10.1093/rheumatology/keaa072
41. Nielen JTH, de Vries F, Dagnelie PC et al. Use of thiazolidinediones and the risk of elective hip or knee replacement:a population based case-control study. Br J Clin Pharmacol 2016; 81: 370–8.
42. Al-Jarallah K, Shehab D, Abdella N et al. Kneeosteoarthritis in type 2 diabetes mellitus: Does insulin therapy retard osteo-phyte formation? Med Princ Pract 2016; 25: 12–7.
43. Eymard F, Parsons C, Edwards MH et al. Statin use and knee osteoarthritis progression: Results from a post-hoc analysisof the SEKOIA trial. Joint Bone Spine 2018; 85: 609–14.
44. Cheng Y-Y, Kao C-L, Lin S-Y et al. Effect of anincreased dosage of statins on spinal degenerative joint disease: a retrospectivecohort study. BMJ Open 2018; 8: e017442.
45. Driban JB, Lo GH, Eaton CB et al. Exploratoryanalysis of osteoarthritis progression among medication users: data from the Osteoarthritis Initiative. Ther Adv Musculoskelet Dis 2016; 8: 207–19.
46. Valdes AM, Abhishek A, Muir K et al. Association of beta-blocker use with less prevalent joint pain and lower opioid requirementin people with osteoarthritis. Arthritis Care Res (Hoboken) 2017; 69: 1076–81.
47. Takamatsu A, Ohkawara B, Ito M et al. Verapamilprotects against cartilage degradation in osteoarthritis by inhibiting Wnt/catenin signaling. PLoS ONE 2014; 9: e92699.

Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-09-2021/osteoartrit_i_metabolicheskiy_sindrom_vzglyad_na_fenotipicheskiy_podkhod/

For citation:Gromova M.A., Kislyak O.A., Starodubova A.V., Liskova J.V., Kelekhsaev P.A. Osteoarthritis and metabolic syndrome: a look at the phenotypical approach. Clinical review for general practice. 2021; 9: 37–42. DOI: 10.47407/kr2021.2.9.00106

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice